Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis

Oncotarget

Volumn 7, Issue 22, 2016, Pages 32375-32393

  Kowalik, Marta Anna ^a   Guzzo, Giulia ^b   Morandi, Andrea ^c   Perra, Andrea ^a   Menegon, Silvia ^d   Masgras, Ionica ^b   Trevisan, Elena ^b   Angioni, Maria Maddalena ^a   Fornari, Francesca ^e   Quagliata, Luca ^f   Ledda Columbano, Giovanna Maria ^a   Gramantieri, Laura ^e   Terracciano, Luigi ^f   Giordano, Silvia ^d   Chiarugi, Paola ^c   Rasola, Andrea ^b   Columbano, Amedeo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

HCC; NRF2; Oxidative phosphorylation; Pentose phosphate pathway; TRAP1

Indexed keywords

CHAPERONE; CYTOKERATIN 19; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA 1; TRANSCRIPTION FACTOR NRF2; TRAP1 PROTEIN; UNCLASSIFIED DRUG; HEAT SHOCK PROTEIN 90; NFE2L2 PROTEIN, HUMAN; TRAP1 PROTEIN, HUMAN; TRAP1 PROTEIN, RAT;

ADOLESCENT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GLUCOSE UTILIZATION; GLYCOLYSIS; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER REGENERATION; MAJOR CLINICAL STUDY; MALE; METABOLISM; METASTASIS; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE PHOSPHORYLATION; PARTIAL HEPATECTOMY; PENTOSE PHOSPHATE CYCLE; RAT; ANIMAL; CELL TRANSFORMATION; DRUG EFFECTS; ENERGY METABOLISM; FISCHER 344 RAT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LIVER CELL; LIVER TUMOR; MIDDLE AGED; NUCLEAR REPROGRAMMING; PATHOLOGY; PRECANCER; RNA INTERFERENCE; SECONDARY; TIME FACTOR; TUMOR CELL CULTURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; CELLULAR REPROGRAMMING; ENERGY METABOLISM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSEPHOSPHATE DEHYDROGENASE; GLYCOLYSIS; HEPATOCYTES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; KERATIN-19; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NF-E2-RELATED FACTOR 2; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE PATHWAY; PRECANCEROUS CONDITIONS; RATS, INBRED F344; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 84973571937     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8632     Document Type: Article

References (39)

1. Ward PS and Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012; 21:297-308.
2. Hsu PP and Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134:703-707.
3. Vander Heiden MG, Cantley LC and Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324:1029-1033.
4. Warburg O. On the origin of cancer cells. Science. 1956; 123:309-314.
5. Schulze A and Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012; 491:364-373.
6. Patra KC and Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014; 39:347-354.
7. Gaude E and Frezza C. Defects in mitochondrial metabolism and cancer. Cancer & Metabolism. 2014; 2:10.
8. Hensley CT, Wasti AT and DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Investi. 2013; 123:3678-3684.
9. Levine AJ and Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010; 330:1340-1344.
10. Vousden KH and Ryan KM. p53 and metabolism. Nat Rev Cancer. 2009; 9:691-700.
11. Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013; 123:3664-3671.
12. Dang CV. MYC on the path to cancer. Cell. 2012; 149:22-35.
13. Hayes JD and Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014; 39:199-218.
14. Jaramillo MC and Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes & Development. 2013; 27:2179-2191.
15. Li Z, Yang P and Li Z. The multifaceted regulation and functions of PKM2 in tumor progression. Biochim Biophys Acta. 2014; 1846:285-296.
16. Lee P, Vousden KH and Cheung EC. TIGAR, TIGAR, burning bright. Cancer & Metabolism. 2014; 2:1.
17. Icard P, Poulain L and Lincet H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim Biophys Acta. 2012; 1825:111-116.
18. Rasola A, Neckers L and Picard D. Mitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells. Trends Cell Biol. 2014; 24:455-463.
19. Yoshida S, Tsutsumi S, Muhlebach G, Sourbier C, Lee MJ, Lee S, Vartholomaiou E, Tatokoro M, Beebe K, Miyajima N, Mohney RP, Chen Y, Hasumi H, et al. Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci USA. 2013; 110:E1604-1612.
20. Guzzo G, Sciacovelli M, Bernardi P and Rasola A. Inhibition of succinate dehydrogenase by the mitochondrial chaperone TRAP1 has anti-oxidant and anti-apoptotic effects on tumor cells. Oncotarget. 2014; 5:11897-11908. doi:10.18632/oncotarget.2472.
21. Sciacovelli M, Guzzo G, Morello V, Frezza C, Zheng L, Nannini N, Calabrese F, Laudiero G, Esposito F, Landriscina M, Defilippi P, Bernardi P and Rasola A. The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. Cell Metab. 2013; 17:988-999.
22. Yang M, Soga T and Pollard PJ. Oncometabolites: linking altered metabolism with cancer. J Clin Invest. 2013; 123:3652-3658.
23. Solt DB, Medline A and Farber E. Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis. The American J Pathol. 1977; 88:595-618.
24. Kowalik MA, Sulas P, Ledda-Columbano GM, Giordano S, Columbano A and Perra A. Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis. Oncotarget. 2015; 6:38749-38763. doi:10.18632/oncotarget.5501.
25. Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A and Thorgeirsson SS. Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology. 2010; 51:1401-1409.
26. Petrelli A, Perra A, Cora D, Sulas P, Menegon S, Manca C, Migliore C, Kowalik MA, Ledda-Columbano GM, Giordano S and Columbano A. MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). Hepatology. 2014; 59:228-241.
27. Enomoto K and Farber E. Kinetics of phenotypic maturation of remodeling of hyperplastic nodules during liver carcinogenesis. Cancer Res. 1982; 42:2330-2335.
28. Mathupala SP, Ko YH and Pedersen PL. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta. 2010; 1797:1225-1230.
29. Chiara F, Castellaro D, Marin O, Petronilli V, Brusilow WS, Juhaszova M, Sollott SJ, Forte M, Bernardi P and Rasola A. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PloS One. 2008; 3:e1852.
30. Masgras I, Rasola A and Bernardi P. Induction of the permeability transition pore in cells depleted of mitochondrial DNA. Biochim Biophys Acta. 2012; 1817:1860-1866.
31. Pantic B, Trevisan E, Citta A, Rigobello MP, Marin O, Bernardi P, Salvatori S and Rasola A. Myotonic dystrophy protein kinase (DMPK) prevents ROS-induced cell death by assembling a hexokinase II-Src complex on the mitochondrial surface. Cell Death Dis. 2013; 4:e858.
32. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M and Motohashi H. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012; 22:66-79.
33. Singh A, Happel C, Manna SK, Acquaah-Mensah G, Carrerero J, Kumar S, Nasipuri P, Krausz KW, Wakabayashi N, Dewi R, Boros LG, Gonzalez FJ, Gabrielson E, et al. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest. 2013; 123:2921-2934.
34. Giannoni E, Taddei ML, Morandi A, Comito G, Calvani M, Bianchini F, Richichi B, Raugei G, Wong N, Tang D and Chiarugi P. Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread. Oncotarget. 2015; 6:24061-24074. doi:10.18632/oncotarget.4448.
35. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
36. Pavlova NN and Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23:27-47.
37. Mattu S, Fornari F, Quagliata L, Perra A, Angioni MM, Petrelli A, Menegon S, Morandi A, Chiarugi P, Ledda-Columbano GM, Gramantieri L, Terracciano L, Giordano S, et al. The metabolic gene HAO2 is down regulated in mouse, rat and human hepatocellular carcinoma and correlates with metastasis and poor survival. J Hepatol. 2016; 64:891-898.
38. Zavattari P, Perra A, Menegon S, Kowalik MA, Petrelli A, Angioni MM, Follenzi A, Quagliata L, Ledda-Columbano GM, Terracciano L, Giordano S and Columbano A. Nrf2, but not beta-catenin, mutation represents an early event in rat hepatocarcinogenesis. Hepatology. 2015; 62:851-862.
39. Follenzi A, Benten D, Novikoff P, Faulkner L, Raut S and Gupta S. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest. 2008; 118:935-945.